Telomir Pharmaceuticals, Inc. — Form 8-K
Filed September 16, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 8/100
What the filing says
Telomir Pharmaceuticals filed an 8-K on September 16, 2026, reporting Item 5.07 (Submission of Matters to a Vote of Security Holders) for a meeting period ending September 11, 2026. The filing contains no financial data, transaction details, dollar amounts, vote counts, or material outcomes—only metadata and XBRL formatting files. Specific voting results, proposals, or business impacts are not disclosed in this filing.
Why this rating
Routine 8-K disclosure of shareholder meeting; no substantive business information or metrics provided; boilerplate regulatory filing.
Extracted items
- 5.07 shareholder vote
- 9.01 exhibits
See more from September 16, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.